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Abstract High mobility group protein box1 (HMGB1)
and its receptor—receptor for advanced glycation end pro-
ducts (RAGE) are pivotal factors in the development and
progression of many types of tumor, but the role of HMGB1-
RAGE axis in hepatocellular carcinoma (HCC) especially
its effects on metastasis and recurrence remains obscure.
Here, we report the role of HMGB1-RAGE axis in the
biological behaviors of HCC cell lines and the underlying
molecular mechanism. We show that the expressions of
HMGB1, RAGE, and extracellular HMGB1 increase
consistently according to cell metastasis potentials, while
the concentration of soluble form of RAGE (sRAGE) is
inversely related to metastasis potential of HCC cells. Fur-
thermore, our data show that rhHMGB1 promotes cellular
proliferation, migration, and invasion, and increases the
level of nuclear factor kappa B (NF-jB), while administra-
tions of HMGB1-siRNA, RAGE-siRNA, anti-HMGB1
neutralizing antibody, anti-RAGE neutralizing antibody,
and sRAGE inhibit cellular proliferation, migration, and
invasion. Moreover, we also demonstrate that the expression
of NF-rB is inhibited by knockdown of HMGB1 or RAGE.
Collectively, these data demonstrate that HMGB1 activates
RAGE signaling pathways and induces NF-rB activation to
promote cellular proliferation, invasion, and metastasis, in
HCC cell lines. Taken together, HMGB1-RAGE axis may
become a potential target in HCC therapy.
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Abbreviations
HMGB1 High mobility group protein box1
HCC Hepatocellular carcinoma
NF-jB Nuclear factor kappa B
RAGE Receptor for advanced glycation end products
sRAGE Soluble form of RAGE
rhHMGB1 Recombinant human HMGB1
Introduction
Hepatocellular carcinoma (HCC) is one of the most com-
mon malignancies around the world, especially in Asia and
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Africa. Despite the progress attained in molecular biology
and cancer therapy recent years, the remote prognosis of
HCC remains dismal, which was mainly attributed to the
high incidence of distant metastasis, therapy resistance, and
local recurrence [1]. However, the underlying molecular
mechanism responsible for invasion and metastasis of HCC
still remains obscure. Therefore, it is of great significance
to make further study about the molecular mechanism of
metastasis and invasion of HCC.
High mobility group protein box1 (HMGB1) is a
nonhistone chromatin-binding protein. The function of
HMGB1 is complicated and related to its cellular locali-
zation. In the nucleus, HMGB1 binds with DNA and
serves as a structural component. Nevertheless, it can be
released into the extracellular environment during necro-
sis or in response to certain stimulations, such as hypoxia
and endotoxin [2]. Through the binding with high affinity
to several receptors, extracellular HMGB1 plays a critical
role in the development of various diseases, such as
vascular disease, diabetes, cancer, and neurodegeneration
[3]. Receptor for advanced glycation end products
(RAGE), which is a member of the immunoglobulin
superfamily of cell surface molecules, is a central cell
surface receptor for HMGB1 [4–6]. Experimental data
have shown that through the activation of various sig-
naling pathways such as NF-rB, Racl/Cdc42, MAPKs,
PI3K/Akt, ERK1/2, SrcK, and HMGB1-RAGE interaction
is deeply involved in tumor growth, migration, and
metastases [4, 7]. HMGB1 is highly expressed in many
types of tumors, such as pancreatic cancer, colon cancer,
and melanoma [8]. Previous study found that HMGB1
and RAGE can modulate the proliferation of HCC cells
and induce apoptosis, indicating that HMBG1-RAGE axis
may play a significant role in the development of HCC [9,
10].
NF-jB is a dimeric protein widespread in the cyto-
plasm. Through the gene products and downstream sig-
naling pathways, NF-jB participated in numerous
pathological processes, such as inflammation, immune
response, apoptosis, tumor and cell cycle regulation, cell
differentiation, and so on [11–13]. Activated NF-jB is
highly expressed in inflammation-related HCC and serves
as a bridge from chronic inflammation to carcinogenesis
[14–16]. Accumulating evidences showed that HMGB1
can promote the activation of NF-jB through binding
with RAGE in macrophages and oral squamous cell car-
cinoma [17, 18].
However, the biological function of HMGB1-RAGE
axis in the invasion of HCC is yet not fully understood. In
this study, we evaluate that whether HMGB1 can induce
NF-jB activation through the interaction with RAGE and
subsequently contribute to tumor invasiveness in HCC
cells.
Materials and methods
Cell culture and regents
Three human HCC cell lines with unique metastatic char-
acteristics were investigated. Hep3B cell line with the
lowest metastasis potential [19] was purchased from Cell
Bank of the Chinese Academy of Sciences (Shanghai,
China); MHCC97L cell line with the moderate metastasis
potential and HCCLM3 cell line with the highest metas-
tasis potential were kindly obtained from the Liver Cancer
Institute of Fudan University (Shanghai, China) [20, 21].
All cell lines were maintained in DMEM medium (Gibico),
supplemented with 10 % fetal bovine serum (FBS, Gibico),
penicillin (100 U/ml), and streptomycin (100 lg/ml). Cells
were incubated at 37 C with 5 % CO2, and were harvested
with 0.25 % trypsin/EDTA (Gibico) in their logarithmic
growth phase, washed with PBS, and resuspended in new
media. The reagents used were as follows: Recombinant
human HMGB1 (rhHMGB1) and recombinant human
RAGE/Fc chimera, homologs to soluble form of RAGE
(sRAGE), utilized as ex-RAGE were purchased from R&D
systems (Inc., Minneapolis, MN, USA). The antibodies
used were as follows: anti-HMGB1 neutralizing antibody,
anti-RAGE neutralizing antibody (Abcam), anti-GAPDH
(Cell Signal Technology), anti-NF-jB P50, anti-NF-jB
P65, and goat IgG (Santa Cruz).
ELISA
Hep3B, MHCC97L, and HCCLM3 cells were plated in
6-well plates at a density of 1 9 104 cells/well. After
incubation for 48 h, supernatants were collected to detect
the release levels of extracellular HMGB1 and sRAGE by
ELISA (R&D system), according to the manufacturer’s
instructions.
HMGB1 and RAGE knockdown by siRNA
HCCLM3 cells were seeded in 6-well plates at a density of
1 9 105 cells/well to achieve a confluence of 80–90 %
overnight. Then, HMGB1-siRNA, RAGE-siRNA, and
negative control siRNA (GenePharma RNAi Company,
Shanghai, China) were transfected into cells, respectively,
using transfection reagent (lipofectamine 2000, Invitrogen)
according to the manufacturer’s instructions.
Cell viability assay
Both trypan blue exclusion and MTT methods were
employed to assess with the cell viability of HCCLM3
cells. After incubation for 24–72 h, 0.5 mg/ml MTT was
added to fresh medium, then cells were incubated for an
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additional 4 h. Afterward, the formazan crystals were dis-
solved in 150 ll dimethyl sulphoxide (DMSO, Sigma-
Aldrich) and measured optical density (OD) at double
wavelength (405, 630 nm) with Multiskan Ascent System
(Thermo).
RT-PCR
Total RNA was extracted with Trizol (Invitrogen, USA)
from cells. 1 lg of RNA was reverse transcribed into
cDNA using the Premium First Strand cDNA Synthesis Kit
(Fermentas). PCR amplifications followed an initial dena-
turation at 95 C for 5 min, 30 cycles consisting of 95 C
for 30 s, 65 C for 30 s, and 72 C for 1 min, and finally
stored at 72 C for 7 min. PCR products were separated by
electrophoresis using 2 % agarose gels. PCR band inten-
sities were compared to b-actin using the Image J (National
Institutes of Health, USA). Quantity RT-PCR reactions
were performed with a Applied Biosystem 7500 Real-Time
PCR System at 50 C for 2 min, 95C for 2 min, 40 cycles
of 95 C for 15 s, 60 C for 32 s. 20 ll amplification
reactions were carried out containing 10 ll 2 9 Platinum
SYPR Green qPCR SuperMix-UDG (Invitrogen), 1 ll
primers, and 1 ll cDNA.
Western blotting
Whole cell protein was extracted with Radio-Immunopre-
cipitation Assay (RIPA, Beyotime Institute of Biotech-
nology, China). Protein samples were separated by
12.5 % SDS-PAGE and transferred to PVDF membranes
(0.45 lm, Millipore) and blocked for 1 h with 5 % bovine
serum albumin (BSA), 0.1 % Tween-20 in TBS. The
membranes were then washed and incubated separately with
the following primary antibodies: anti-HMGB1 (1 lg/ml),
anti-RAGE (2 lg/ml), and anti-GAPDH. After 1 h at room
temperature, the goat anti-rabbit or goat anti-mouse IgG
secondary antibodies (1:5,000 dilution)were used to incu-
bate another an hour. After washing, the immunoreactive
complexes were detected with ECL chemiluminescence
reagents (Invitrogen). ImageJ was used to measure the
density of the bands imaged by X-ray films.
Cell invasion assay
Cell invasion was studied using Corning Transwell poly-
carbonate membrane inserts with 24 pores (pore size
8.0 lm, membrane diameter 6.5 mm). The inserts were set
into 24-well plates to form two champers, and the upper
chambers were precoated with Matrigel Basement Mem-
brane Matrix (BD Biosciences-Discovery Labware).
HCCLM3 cells in the logarithmic growth phase were
trypsinized and resuspended in nonserum containing
DMEM media. Cells in 300 ll DMEM media with a
density of 5 9 103 cells/ml were plated in the upper
chambers. 500 ll DMEM medium with 10 % FBS was
used as a chemoattractant in the lower chamber. Cell
invasion was allowed to progress for 24 h at 37 C with
5 % CO2. Afterward, the Matrix gel and cells on the top
membrane surface were removed with a cotton swab.
Transwell membranes were then stained with crystal violet,
and the light microscopy was used to photograph the cells
that migrated through the membrane to the lower surface.
The migrating cells were quantified by dissolving the
purple crystals on the membranes in 500 ll 10 % acetic
acid, and measuring their OD values at 570 nm by Mul-
tiskan Ascent.
Wound healing assay
Wound healing assay was performed to evaluate cell
motility of HCCLM3 cells. Every 0.5 cm a line across the
hole was drawn on the basal sides of 12-well plates.
HCCLM3 cells were trypsinized, resuspended in nonserum
containing DMEM medium. A total of 5 9 105 cells were
plated into the holes for 24 h to achieve a subconfluence.
Scraping cells with a sharp tip vertically to the marked
lines and washing with PBS, a cell-free area was made.
Cells migrating into the scraped areas were counted after 0,
6, 12, and 24 h, respectively.
Statistical analyses
Results are expressed as the mean ± standard error of the
mean (SEM). Student’s t test or one-way ANOVA test
was used for statistical analysis performed using SPSS
version 16.0. P \ 0.05 was considered to be statistically
significant.
Results
HMGB1 and RAGE are expressed highly in HCCLM3
cells
To study the role of HMGB1 and RAGE in HCC cells, we
first examined the expressions of HMGB1 and RAGE in
HCC cells with distinct metastasis potentials by RT-PCR
and western blot. All three HCC cells expressed HMGB1
and RAGE. Compared with Hep3B and MHCC97L cells,
HCCLM3 cells expressed the highest HMGB1 and RAGE
mRNA (Fig. 1a). Concomitantly, HMGB1 and RAGE
proteins were significantly increased in HCCLM3 cells
(Fig. 1b). These results indicate that the expressions of
HMGB1 and RAGE mRNA and proteins are related to the
metastasis potentials of HCC cells.
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Extracellular HMGB1 and sRAGE are increased
in HCCLM3 cells
ELISA results showed that HMGB1 was released the
highest in HCCLM3 cells (1041.667 ± 39.425 pg/ml)
than that in Hep3B cells (709.667 ± 62.581 pg/ml)
(P \ 0.01), or MHCC97L cells, respectively (761.667 ±
96.407 pg/ml) (P \ 0.01) (Fig. 2a). The concentration of
sRAGE in the supernatants collected from HCCLM3 cells
(22.520 ± 0.935 pg/ml) was less than that from Hep3B
cells (31.903 ± 2.984 pg/ml) (P \ 0.05), or MHCC97L
cells (24.966 ± 3.212 pg/ml) (P \ 0.05), respectively
(Fig. 2b). It is suggested that the release level of HMGB1
or sRAGE extracellularly is associated with the metastasis
potentials of HCC cells.
HMGB1 antibody, RAGE antibody, or sRAGE
attenuates survival rate of HCCLM3 cells,
while HMGB1 increases it
To explore the role of the HMGB1-RAGE axis on the cell
viability of HCC cells, HCCLM3 cells were treated with
anti-HMGB1 neutralizing antibody, anti-RAGE neutraliz-
ing antibody, exogenous sRAGE protein, and recombinant
human HMGB1(rhHMGB1), respectively. The work con-
centrations of recombinant human HMGB1 and anti-
HMGB1 neutralizing antibody were 50 and 20 ng/ml,
respectively. HCCLM3 cells were incubated for 24 h with
varying concentrations (50, 100, 150, and 200 ng/ml) of
anti-RAGE neutralizing antibody or sRAGE, respectively.
MTT assay results showed that anti-RAGE neutralizing
antibody and sRAGE significantly reduced the cell viabil-
ity of HCCLM3 cells in a concentration-dependent manner,
and both reached a peak at 150 ng/ml (Fig. 3a). Thus, the
optimal work concentrations of anti-RAGE neutralizing
antibody and sRAGE were determined as 150 ng/ml.
The results showed that anti-RAGE neutralizing anti-
body, anti-HMGB1 neutralizing antibody, and sRAGE
started to reduce the living rate of HCCLM3 cells from
24 h and reached a lowest level at 72 h by the trypan blue
exclusion assay (Fig. 3b). MTT assay also showed that the
cell viability of HCCLM3 cells was significantly attenuated
by anti-RAGE neutralizing antibody, anti-HMGB1 neu-
tralizing antibody, and sRAGE, while increased by
rhHMGB1 at 48 h (Fig. 3c). These findings indicated that
blockade of HMGB1 and RAGE interaction correlates with
the survival of HCC cells.
Fig. 1 HMGB1 and RAGE were expressed highly in HCCLM3 cells.
a Relative expression of HMGB1 or RAGE mRNA normalized to b-
actin was measured by qRT-PCR in Hep3B, MHCC97L, and HCCLM3
cells. b Expression of HMGB1 or RAGE protein in the three HCC cell
lines was examined by Western blot. GAPDH was used as an internal
control for quantity analysis. (**P \ 0.01, *P \ 0.05)
Fig. 2 Extracellular HMGB1,
and sRAGE level in the
supernatants of HCC cells. The
release level of extracellular
HMGB1 (a) and sRAGE
(b) was measured by ELISA in
the supernatants of Hep3B,
MHCC97L, and HCCLM3
cells. (*P \ 0.05, **P \ 0.01)
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HMGB1 siRNA and RAGE siRNA decrease cell
viability of HCCLM3 cells
To test the hypothesis that HMGB1 and RAGE expressions
promote HCC cells to survive, we then defined specific
siRNAs-targeted HMGB1 gene and RAGE gene, respec-
tively, which were instantly transfected into HCCLM3
cells. HMGB1 mRNA and RAGE mRNA expressions were
significantly decreased by specific HMGB1-siRNA and
RAGE-siRNA, respectively (Fig. 4a). The results showed
that targeted knockdown of HMGB1 or RAGE decreased
the cell viability of HCCLM3 cells, which was not
retrieved by adding ectogenic rhHMGB1 (Fig. 4b).
Invasion and mobility activity of HCCLM3 cells were
inhibited by HMGB1/RAGE siRNA or antibody
Transwell assay showed that knockdown of HMGB1 and
RAGE evidently reduced the cell invasive ability of
HCCLM3 cells, respectively. We also observed that treat-
ments with anti-HMGB1 antibody, anti-RAGE antibody, or
sRAGE significantly decreased the invasion of HCCLM3
cells, while rhHMGB1 actively facilitated it (Fig. 5a, b).
Consistent with these findings, HCCLM3 cells treated with
HMGB1 siRNA, RAGE siRNA, anti-RAGE neutralizing
antibody, and sRAGE, respectively, displayed a consider-
ably decrease in the cell mobility at 12 and 24 h (Fig. 5c),
while HMGB1 obviously promoted cell mobility at 24 h
(Fig. 5d). Moreover, the effect of HMGB1 on cell mobility
was abolished by RAGE-siRNA (Fig. 5c), indicating that
HMGB1 promotes the mobility of HCCLM3 cells in a
RAGE-dependent way.
HMGB1 siRNA and RAGE siRNA decrease
the expressions of NF-jB p50 and p65
Emerging studies have suggested that NF-jB-signaling
pathway contributes to RAGE-driven carcinogenesis. To
explore the effect of HMGB1-RAGE axis on NF-jB
expression, siRNA or antibodies was used to interfere with
the HMGB1-RAGE interaction, which was activated by
exogenous rhHMGB1. Knockdown of HMGB1 or RAGE
Fig. 3 Effects of HMGB1 or RAGE antibodies, sRAGE on the
survival rate of HCCLM3 cells. a Cell viability of HCCLM3 cells was
analyzed by MTT after interacting with anti-RAGE neutralizing
antibody, or human recombinant sRAGE at various concentrations
(50, 100, 150, and 200 ng/ml), respectively for 24 h. RAGE antibody
or sRAGE reduced the cell viability of HCCLM3 cells dose
dependently, and both achieved the greatest growth inhibition at
150 ng/ml. b HCCLM3 cells were treated with anti-HMGB1
neutralizing antibody (20 ng/ml), anti-RAGE neutralizing antibody
(150 ng/ml), and sRAGE (150 ng/ml), respectively for 24–72 h.
Living rate of HCCLM3 cells was decreased by HMGB1 or RAGE
antibody and sRAGE after incubating for 24 h and reached the
greatest surviving inhibition after 72 h. c HCCLM3 cells were
incubated with rhHMGB1 (50 ng/ml) for 48 h, then MTT assay
showed that HMGB1 increased the living rate of HCCLM3 cells.
(*P \ 0.05, **P \ 0.01)
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inhibited NF-jB p50 and p65 mRNA expressions in
HCCLM3 cells, respectively, and we also observed that
NF-jB p50 and p65 mRNA expressions were decreased by
intervention with anti-RAGE neutralizing antibody or
sRAGE. In contrast, HMGB1 slightly increased them
(Fig. 6a, b). The results of NF-jB p50 and p65 proteins are
concomitant with these findings (Fig. 6c, d).
Discussion
Inflammation facilitates the occurrence and development of
tumors. The biologic effects of local inflammation environ-
ment, also known as ‘‘tumor environment,’’ are to maintain
proliferative signals, promote angiogenesis, and boost cell
invasion and metastasis [22]. HMGB1 is constitutively
expressed in the nucleus of cells, and also can be released
outside by tumor cells and by inflammatory cells [23]. In the
nucleus, as a DNA chaperone, it mediates different functions
such as DNA repair and recombination, transcription, and
stabilization of nucleosomes [24]. While extracellular
HMGB1 also participates in many biological processes, such
as immunomodulatory role of sepsis or noninfectious
inflammation, angiogenesis, wound healing, and tumori-
genesis [25]. Constant release of HMGB1 outside the cells,
as a damage-associated molecular pattern (DAMP), creates a
tumor microenvironment, which contributes to the devel-
opment of epithelial malignancies [26].
Emerging evidences have demonstrated that chronic infec-
tion of HBV or HCV can induce the translocation of HMGB1
from nuclei to cytoplasm and extracellular release of HMGB1
[4, 27]. Serum HMGB1 levels were found significantly higher
in HCC patients and overexpression of HMGB1 was associated
with their clinico-pathological features and outcomes [28]. Our
group found that HMGB1 and RAGE can modulate the
proliferation and cell cycle of HCC cells [10]. These findings
show that HMGB1-RAGE axis may play an important role in
the development of HCC, such as the migration and invasion of
HCC. In order to elucidate that, three HCC cell lines with
different metastasis potentials were analyzed in our study. The
expressions of HMGB1 and RAGE increased consistently with
the metastasis potentials of HCC cell lines, indicating that
HMGB1 and RAGE are associated with metastasis potential of
HCC cells. Then, HCCLM3 cell line was selected for further
study, for its highest metastasis potential and richest expres-
sions of HMGB1 and RAGE in all three cell lines. The results
showed RAGE-dependent stimulating responses induced by
rhHMGB1 including increased proliferation, mobility, and
invasion of HCCLM3 cells, whereas down regulation of the
endogenous expression of HMGB1/RAGE by RNAi technol-
ogy or administration of anti-HMGB1/anti-RAGE antibodies
remarkably attenuated these effects. This finding illustrated that
both HMGB1 and RAGE were essential factors in the prolif-
eration, migration, and invasion of HCC cells, with a HMGB1-
RAGE interaction mode. The results also suggested that the
HCCLM3 cells with weakened viability showed low ability of
invasiveness and motility. Reduced viability of HCC cells is
likely contributed to the decline of cell motility and invasive-
ness. We also found that the concentration of HMGB1 in the
supernatants of HCCLM3 cells was much higher compared to
that in low-metastatic MHCC97L cells and nonmetastatic
Hep3B cells. Regarding that cell viability was not obviously
reduced at that time point, it suggested that HMGB1 can be
actively secreted into extracellular environment by HCC cells,
which, thereby participated in the construction of ‘‘tumor
microenvironment.’’
Soluble form of RAGE is the major isoform of RAGE,
mutated from the shedding of extracellular domain of
RAGE or RAGE mRNA selectively splicing (the latter also
known as endogenous secretory RAGE). Due to the
Fig. 4 HMGB1 siRNA and RAGE siRNA decreased the cell
viability of HCCLM3 cells. a Knockdown of HMGB1 or RAGE in
HCCLM3 cells by specific gene-targeted HMGB1-siRNA and
RAGE-siRNA was confirmed by qRT-PCR. Add a descriptive label
of the figure here. b After incubating with HMGB1-siRNA (75 ng/ml),
RAGE-siRNA (75 ng/ml), and rhHMGB1 (50 ng/ml) for 48 h,
the results of MTT assay showed that knockdown of HMGB1 or
RAGE decreased the cell viability of HCCLM3 cells (*P \ 0.05,
**P \ 0.01). NC negative control with a nonsense siRNA sequence
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absence of intracellular domain and membrane mosaic area
of the receptor, sRAGE is deprived of the ability of sig-
naling transduction. Therefore, when HMGB1 combines
with decayed sRAGE, the ability of interacting with
complete RAGE on the cell membrane is attenuated, which
subsequently inhibits its important biological behavior of
tumorigenesis promotion [29, 30]. Studies showed that,
compared to healthy volunteers, the level of sRAGE in
Fig. 5 HMGB1 siRNA and RAGE siRNA attenuated invasion and
mobility of HCCLM3 cells in vitro. HCCLM3 cells were seeded into
the upper chamber of the transwell, treated with HMGB1-siRNA,
RAGE-siRNA, anti-RAGE antibody or sRAGE, and rhHMGB1, and
allowed to invade matrigel for 24 h. a The invasive cells migrating
through the basal membrane to its lower surface were stained with
crystal violet, then were photographed (20 9 10). b The number of
invasive cells was also quantified by dissolving the purple crystals on
the membranes in 500 ll 10 % acetic acid, and measuring their OD
values at 570 nm by Multiskan Ascent. Cell invasion ability was
expressed indirectly by varying OD values. HMGB1 or RAGE
siRNA, HMGB1, or RAGE antibody, and sRAGE inhibited the
invasion ability of HCCLM3 cells, while rhHMGB1 facilitated it
(*P \ 0.05, **P \ 0.01). c, d Migration ability of HCCLM3 cells
was detected by wound healing assay. Incubating for 0, 6, 12, and
24 h, respectively, the number of HCCLM3 cells migrating into the
scraped areas was counted. (*P \ 0.05, **P \ 0.01)
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serum was lower than that from patients of breast cancer
[31] and gastric cancer [32]. Similarly, in this study, we
found that the concentration of sRAGE is negatively
correlated with the metastatic potentials of HCC cell
lines. Meanwhile, administration of exogenous sRAGE
decreased the cell viability, invasion, and mobility, indi-
cating that sRAGE may become a potential therapeutic
target of HCC. However, more evidences from experiments
in vivo and vitro were required. Interestingly, we also
found that knockdown of RAGE showed more apparent
decrease of cell viability, invasion, and mobility than that
of HMGB1, suggesting that other soluble RAGE ligands of
RAGE such as S100, AGEs may also be likely involved in
this process. Soluble RAGE demonstrated by Kalea et al.
[33], acts to inhibit cancer cells by activation of MAPK
families, which may play an important role in tumorigen-
esis and the development of HCC. Whether soluble RAGE
inhibits HCC cells through activating MAPK-signaling
pathway or by other mechanisms remains unclear, and
needs to be elucidated in our future studies.
NF-jB, as a quick responsive transcription factor, is the
converging point of various signaling pathways. In
Fig. 6 Effects of HMGB1 and RAGE on NF-jB expression in
HCCLM3 cells. a Expression of NF-jB p65 or p50 mRNA in
HCCLM3 cells was explored by RT-PCR. b Relative expression of
NF-jB p65 or p50 mRNA was normalized to b-actin. HMGB1 or
RAGE siRNA, HMGB1 or RAGE antibody, and sRAGE inhibited
NF-jB p65 and p50 mRNA expression in HCCLM3 cells, while
rhHMGB1 increased it (*P \ 0.05, **P \ 0.01). c Western blot was
performed to test NF-jB p65 or p50 protein expression in HCCLM3
cells. d Quantity analysis of NF-jB p65 and p50 proteins expression
levels relative to GAPDH. (*P \ 0.05, **P \ 0.01)
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inflammation-related tumor model of animals, the IKKb-
dependent activation of NF-jB is the key process in
inflammation-induced carcinoma. Therefore, we postulated
that the NF-jB-signaling pathway may be engaged in the
biological function of HMGB1-RAGE axis in HCC
development. Our results showed that rhHMGB1 increased
the expression of NF-jB p50 and p65. Conversely,
knockdown of HMGB1 and RAGE specifically by siRNA
significantly reduced the level of NF-jB p50 and p65.
Impacts of HMGB1-RAGE axis on activation of NF-jB-
signaling pathway and its downstream transcriptional
activity in HCC are worthy of being determined in our
future work.
In summary, we demonstrate that HMGB1-RAGE axis
plays a pivotal role in HCC cell invasion and migration.
The expression alteration of NF-jB is also involved in this
process. However, many issues remain unclear: what are
the downstream signaling pathways of HMGB1-RAGE
axis in the development of HCC? Whether NF-jB is
activated in this process or not? Further explorations,
especially in vivo studies are needed to confirm them.
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